|
1
|
Borden EC, Sen GC, Uze G, et al:
Interferons at age 50: past, current and future impact on
biomedicine. Nat Rev Drug Discov. 6:975–990. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Preudhomme C, Guilhot J, Nicolini FE, et
al: Imatinib plus peginterferon alfa-2a in chronic myeloid
leukemia. N Engl J Med. 363:2511–2521. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Simonsson B, Gedde-Dahl T, Markevarn B, et
al: Combination of pegylated IFN-alpha2b with imatinib increases
molecular response rates in patients with low- or intermediate-risk
chronic myeloid leukemia. Blood. 118:3228–3235. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Talpaz M, Hehlmann R, Quintas-Cardama A,
Mercer J and Cortes J: Re-emergence of interferon-alpha in the
treatment of chronic myeloid leukemia. Leukemia. 27:803–812. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jin LH, Tabe Y, Konoplev S, et al: CXCR4
up-regulation by imatinib induces chronic myelogenous leukemia
(CML) cell migration to bone marrow stroma and promotes survival of
quiescent CML cells. Mol Cancer Ther. 7:48–58. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang B, Li M, McDonald T, et al:
Microenvironmental protection of CML stem and progenitor cells from
tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin
signaling. Blood. 121:1824–1838. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Plimack ER, Desai JR, Issa JP, et al: A
phase I study of decitabine with pegylated interferon alpha-2b in
advanced melanoma: impact on DNA methylation and lymphocyte
populations. Invest New Drugs. 32:969–975. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abukawa H, Kaban LB, Williams WB, Terada
S, Vacanti JP and Troulis MJ: Effect of interferon-alpha-2b on
porcine mesenchymal stem cells. J Oral Maxillofac Surg.
64:1214–1220. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oreffo RO, Romberg S, Virdi AS, Joyner CJ,
Berven S and Triffitt JT: Effects of interferon alpha on human
osteoprogenitor cell growth and differentiation in vitro. J Cell
Biochem. 74:372–385. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee BS, Stewart EA, Sahakian M and Nowak
RA: Interferon-alpha is a potent inhibitor of basic fibroblast
growth factor-stimulated cell proliferation in human uterine cells.
Am J Reprod Immunol. 40:19–25. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Leaman DW, Chawla-Sarkar M, Jacobs B, et
al: Novel growth and death related interferon-stimulated genes
(ISGs) in melanoma: greater potency of IFN-beta compared with
IFN-alpha2. J Interferon Cytokine Res. 23:745–756. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hatzfeld A, Eid P, Peiffer I, et al: A
sub-population of high proliferative potential-quiescent human
mesenchymal stem cells is under the reversible control of
interferon α/β. Leukemia. 21:714–724. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Crowder C, Dahle O, Davis RE, Gabrielsen
OS and Rudikoff S: PML mediates IFN-alpha-induced apoptosis in
myeloma by regulating TRAIL induction. Blood. 105:1280–1287. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Everett RD and Chelbi-Alix MK: PML and PML
nuclear bodies: implications in antiviral defence. Biochimie.
89:819–830. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou W and Bao S: PML-mediated signaling
and its role in cancer stem cells. Oncogene. 33:1475–1484. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Salomoni P: Stemming out of a new PML era?
Cell Death Differ. 16:1083–1092. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Salomoni P, Dvorkina M and Michod D: Role
of the promyelocytic leukaemia protein in cell death regulation.
Cell Death Dis. 3:e2472012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun J, Fu S, Zhong W and Huang H: PML
overexpression inhibits proliferation and promotes the osteogenic
differentiation of human mesenchymal stem cells. Oncol Rep.
30:2785–2794. 2013.PubMed/NCBI
|
|
19
|
Conget PA and Minguell JJ: Phenotypical
and functional properties of human bone marrow mesenchymal
progenitor cells. J Cell Physiol. 181:67–73. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sperka T, Wang J and Rudolph KL: DNA
damage checkpoints in stem cells, ageing and cancer. Nat Rev Mol
Cell Biol. 13:579–590. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ben-Porath I and Weinberg RA: When cells
get stressed: an integrative view of cellular senescence. J Clin
Invest. 113:8–13. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Campisi J: Aging, cellular senescence, and
cancer. Annu Rev Physiol. 75:685–705. 2013. View Article : Google Scholar
|
|
23
|
Sikora E, Arendt T, Bennett M and Narita
M: Impact of cellular senescence signature on ageing research.
Ageing Res Rev. 10:146–152. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Upreti M, Koonce NA, Hennings L, Chambers
TC and Griffin RJ: Pegylated IFN-alpha sensitizes melanoma cells to
chemotherapy and causes premature senescence in endothelial cells
by IRF-1 mediated signaling. Cell Death Dis. 1:e672010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li Q, Tang L, Roberts PC, et al:
Interferon regulatory factors IRF5 and IRF7 inhibit growth and
induce senescence in immortal Li-Fraumeni fibroblasts. Mol Cancer
Res. 6:770–784. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Burchert A, Wolfl S, Schmidt M, et al:
Interferon-alpha, but not the ABL-kinase inhibitor imatinib
(STI571), induces expression of myeloblastin and a specific T-cell
response in chronic myeloid leukemia. Blood. 101:259–264. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bischof O, Kirsh O, Pearson M, Itahana K,
Pelicci PG and Dejean A: Deconstructing PML-induced premature
senescence. EMBO J. 21:3358–3369. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vernier M, Bourdeau V, Gaumont-Leclerc MF,
et al: Regulation of E2Fs and senescence by PML nuclear bodies.
Genes Dev. 25:41–50. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kruse JP and Gu W: Modes of p53
regulation. Cell. 137:609–622. 2009. View Article : Google Scholar
|
|
30
|
Sung KS, Lee YA, Kim ET, Lee SR, Ahn JH
and Choi CY: Role of the SUMO-interacting motif in HIPK2 targeting
to the PML nuclear bodies and regulation of p53. Exp Cell Res.
317:1060–1070. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xue Y, Li L, Zhang D, et al: Telomerase
suppression initiates PML-dependent p53 activation to inhibit
bladder cancer cell growth. Oncol Rep. 24:1551–1559.
2010.PubMed/NCBI
|
|
32
|
Midgley CA and Lane DP: p53 protein
stability in tumour cells is not determined by mutation but is
dependent on Mdm2 binding. Oncogene. 15:1179–1189. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Michael D and Oren M: The p53-Mdm2 module
and the ubiquitin system. Semin Cancer Biol. 13:49–58. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dai C and Gu W: p53 post-translational
modification: deregulated in tumorigenesis. Trends Mol Med.
16:528–536. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Carracedo A, Ito K and Pandolfi PP: The
nuclear bodies inside out: PML conquers the cytoplasm. Curr Opin
Cell Biol. 23:360–366. 2011. View Article : Google Scholar : PubMed/NCBI
|
